Lumexa Imaging (NASDAQ:LMRI) Upgraded to Strong-Buy at KeyCorp
by Mitch Edgeman · The Markets DailyKeyCorp upgraded shares of Lumexa Imaging (NASDAQ:LMRI – Free Report) to a strong-buy rating in a research report report published on Thursday,Zacks reports.
A number of other research firms have also commented on LMRI. Wall Street Zen lowered Lumexa Imaging from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings reissued a “sell (d)” rating on shares of Lumexa Imaging in a research note on Tuesday. Barclays increased their target price on Lumexa Imaging from $9.00 to $13.00 and gave the stock an “overweight” rating in a report on Friday, August 28th. Finally, Deutsche Bank Aktiengesellschaft set a $16.00 target price on Lumexa Imaging in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $17.50.
Check Out Our Latest Analysis on LMRI
Lumexa Imaging Stock Down 2.6%
Shares of LMRI opened at $9.88 on Thursday. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 1.40. The stock has a market cap of $949.17 million and a price-to-earnings ratio of -20.16. Lumexa Imaging has a 12 month low of $6.45 and a 12 month high of $19.45. The company has a 50-day moving average price of $11.39 and a two-hundred day moving average price of $10.42.
Lumexa Imaging (NASDAQ:LMRI – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. The company had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Equities analysts predict that Lumexa Imaging will post 0.25 EPS for the current fiscal year.
Institutional Trading of Lumexa Imaging
A number of institutional investors have recently bought and sold shares of LMRI. Strs Ohio bought a new position in shares of Lumexa Imaging in the 1st quarter worth $38,000. PNC Financial Services Group Inc. bought a new position in Lumexa Imaging during the first quarter worth about $63,000. State of Wyoming bought a new stake in shares of Lumexa Imaging in the 1st quarter valued at about $91,000. AXQ Capital LP acquired a new stake in shares of Lumexa Imaging in the 2nd quarter valued at approximately $128,000. Finally, Bank of America Corp DE acquired a new position in Lumexa Imaging during the second quarter valued at approximately $200,000.
Lumexa Imaging Company Profile
Lumexa Imaging, Inc (NASDAQ: LMRI) is an outpatient diagnostic imaging company that provides medical imaging services to patients and referring healthcare providers in the United States. Its services are designed to support the diagnosis, monitoring and management of a wide range of medical conditions.
The company’s imaging capabilities include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET/CT), ultrasound, mammography and X-ray services. Lumexa also provides related radiology and imaging-support services through its outpatient centers and other care-delivery arrangements.
Lumexa Imaging was formerly known as Akumin Inc and adopted the Lumexa Imaging name as part of its corporate rebranding.